

# R O O G R A M

## ADVANCED OVARIAN CANCER: OPTIMAL THERAPY. UPDATE

### ● WELCOME

M. LLOMBART (VALENCIA)

### 09.00 - 11.00: SESSION 1 - SURGERY

#### ● SURGICAL STAGING / EUROPEAN GUIDELINES FOR STAGING

J.B. TRIMBOR (LEIDEN)

#### ● INTERVENTION DEBULKING SURGERY

M.E.L. VAN DER BURG (ROTTERDAM)

#### ● SECONDARY CYTOREDUCTIVE SURGERY / PALLIATIVE SURGERY

S. PECORELLI (MILAN)

#### ● SURGICAL IMPLICATIONS OF CA-125

G. RUSTIN (NORTHWOOD, MIDDLESEX)

### COFFEE BREAK

### 11.30-13.30: SESSION 2 - CHEMOTHERAPY

#### ● THE ROLE OF

DOXORUBICIN (META-ANALYSIS)

M.E. GORE (LONDON)

#### OTHER ANTHRACYCLINES

J.B. VERMORREN (AMSTERDAM)

#### HEXAMETHYLMELAMINE

G. RUSTIN (NORTHWOOD, MIDDLESEX)

#### OTHER DRUGS

E.A. EISENHAEUER (KINGSTON, ONTARIO)

#### ● IS TP THE STANDARD IN FIRST-LINE TREATMENT?

##### THE GOG EXPERIENCE

M. MARKMAN (CLEVELAND, OHIO)

##### THE EORTC EXPERIENCE

M.J. FIGGART (BRUSSELS)

### LUNCH

### 14.30-16.30: SESSION 3 - CHEMOTHERAPY

#### ● REDUCTION OF NONHEMATOLOGIC TOXICITY

E.A. EISENHAEUER (KINGSTON, ONTARIO)

#### ● INTRAPERITONEAL CHEMOTHERAPY

M. ROTHENBERG (SAN ANTONIO, TEXAS)

#### ● CHEMOTHERAPY RESISTANCE

E.G.E. DE VRIES (GRONINGEN)

#### ● HIGH-DOSE CHEMOTHERAPY

J. CROWN (DUBLIN)

### 16.30-17.30: REMARKS

J.B. VERMORREN (AMSTERDAM)

A. POVEDA (VALENCIA)

